{"path":"Images/Pasted image 20240311153210.png","text":"Gastic Most common GIT type _ Appendix | _GIT (75%) Right-sided heart faure =21~ Up to 40% o carcingid syndromes Rectum 1 Garcinoid tumours Leftsided heart falre __uncommon Mostcommon ronGIType L B () un ronchial instabili ot smokingreaied VS instabil pertension or hypotension o NoniT Pancreas Bronchospasm OveryTestle {Oer) Endocarits prophylaxis 10% of all arcinoid tumours Location and type of arcinoid tumour GIT carcinoids with ver metastasis Garcinoid syndrome. Occurs in Non-GIT carcincids Trigg Flushing Carcinoid heart disease \" Predictors of priop complications Diarrhoea High urinary S-HIAA o sas | Bronchospasm e Dyspnoea Temp Hypotension istor Help difierentiating cause of hypotension M MEN-1 syndrome (10%) cve Assosiated May be hard to interpret with TRITS. Consider Neurofibromatosis ToE 5 o Carcinoid syndrome - AMx | Others ~SYS histo Octreotide 50 to 100 meg SC before induction Functional capaci ‘Consider sedaive premed to reduce ans o Ocreotide Bronchodiators Readily available Rx_[ antnistamine Vasopressor / vasoiators (Gonsutaton} SHT antagonists e e {Ptan} / — Dilte to 10 megimL ~ BSLUSE.LFT { i o 10 | Bioods SIS, R Infusion: 100 megihour 1V intraop con 7 {Sntmescnssomngn/ Urinary S:HIAA T I Endocardial ibrosis Anaigesia \\ Echo Valviar abormaii p Tricuspid valve ntraop intabil xR Post i bronchial Significant cadiac involvement / co-morbidty | ICUHDU admission top Consider chest CT /MR Residual aciive carcinoid Discuss with endocrinology team re periop ocireotide Rx Postop weaning o octreotide Rx__ Endocrinology consuit | st corcined hoart Cardiology referral Continue Rx Optimisation |- significant carcinoid heart disease ety sk Consider valve replacement irst Treat mediator effects ith octreotde. (Goai) Ocireotide Rx should be strted at least 2 weeks prior Avoid triggering mediator release Correct any hypovolaemia, BSL or electrlyte distrbances Avoid precipitating right heart failure","libVersion":"0.3.2","langs":"eng"}